Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Flourish Research ("Flourish" or the "Company"), a leading multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas ...
Through the strategic alliance, Novotech and Wonju Severance Christian Hospital aim to set new leverage their combined expertise to set new standards in clinical trials and medical services. The ...
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...
Oncology studies present unique challenges when it comes to participant treatment, resupply, and study management.
Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...
Sunnybrook’s donor community has kicked in another $2 million for the study. The team aims to help improve access to and integration of mental health and addictions services to youth and families in ...
CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...
Ona Therapeutics ("Ona"), a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), today announced key ...
Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 ...
19h
AVEO Oncology, an LG Chem company ("AVEO"), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, presented two posters during the 2025 ...
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback